about
New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptorsClinical implications of drug-drug interactions with P2Y12 receptor inhibitors.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention.Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelorPhenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study
P2860
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Ticagrelor: from discovery to Phase III clinical trial.
@en
Ticagrelor: from discovery to Phase III clinical trial.
@nl
type
label
Ticagrelor: from discovery to Phase III clinical trial.
@en
Ticagrelor: from discovery to Phase III clinical trial.
@nl
prefLabel
Ticagrelor: from discovery to Phase III clinical trial.
@en
Ticagrelor: from discovery to Phase III clinical trial.
@nl
P2860
P356
P1433
P1476
Ticagrelor: from discovery to Phase III clinical trial.
@en
P2093
Bernd Jilma
P2860
P304
P356
10.2217/FCA.10.89
P577
2010-11-01T00:00:00Z